The study followed 38 immunocompromised adults, aged 64 to 72, who received either the Arexvy or Abrysvo RSV vaccine. Researchers found that people aged 60 and older who are immunocompromised ...

Researchers have shown that people 60 years or older with weakened immunity do not respond as strongly to vaccines against the respiratory syncytial virus (RSV) as people in the same age group with ...

Respiratory illness activity is currently considered "high" in the United States, according to the CDC. In one state, it is ...